NewcelX Ltd. (NCEL) lines up $1.4M private placement and warrants
Rhea-AI Filing Summary
NewcelX Ltd. entered into definitive securities purchase agreements for a private placement financing with certain accredited investors. Investors agreed to purchase 347,134 common shares, or pre-funded warrants in lieu thereof, at $4.033 per share, plus common warrants to purchase up to 347,134 common shares at an exercise price of $4.437 per share. The common warrants have a five-year term. The transaction is expected to yield $1.4 million in gross proceeds, with approximately $1.5 million of additional gross proceeds possible upon full cash exercise of the common warrants.
NewcelX plans to use the net proceeds, together with its current cash and a previously announced $25 million equity line, primarily to advance NCEL-101, its lead Type 1 Diabetes program in collaboration with Eledon Pharmaceuticals, and for working capital and general corporate purposes. Closing is expected on or about August 14, 2026, subject to customary closing conditions. The company agreed for 60 days not to enter agreements to issue additional common shares or equivalents or to file registration statements, subject to customary exceptions, and will use reasonable best efforts to file a resale registration statement within 45 calendar days. The securities are being issued in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D to accredited investors or qualified institutional buyers, without general solicitation.
Positive
- None.
Negative
- None.
Key Figures
Common shares in private placement: 347,134 shares
Purchase price per share: $4.033 per share
Common warrant coverage: 347,134 shares
+5 more
8 metrics
Common shares in private placement
347,134 shares
Number of common shares or pre-funded warrants investors agreed to purchase
Purchase price per share
$4.033 per share
Price for each common share or pre-funded warrant in the Offering
Common warrant coverage
347,134 shares
Maximum number of common shares underlying the common warrants
Common warrant exercise price
$4.437 per share
Exercise price for the common warrants issued in the Offering
Initial gross proceeds
$1.4 million
Expected gross proceeds to NewcelX from the private placement
Potential additional gross proceeds
approximately $1.5 million
Additional gross proceeds if common warrants are cash exercised in full
Equity line capacity
$25 million
Size of previously announced equity line referenced as part of funding
No-issuance period
60 days
Period with restrictions on new equity issuances and registration statements, subject to exceptions
Key Terms
private placement, pre-funded warrants, common warrants, equity line, +2 more
6 terms
private placement financial
"entered into definitive securities purchase agreements for a private placement financing"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
pre-funded warrants financial
"common shares, par value CHF 0.05 per share, or pre-funded warrants in lieu thereof"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
common warrants financial
"common warrants to purchase up to 347,134 common shares at an exercise price"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
equity line financial
"together with its current cash position, and previously announced $25 million equity line, primarily"
An equity line is a financing arrangement that lets a company raise cash over time by issuing new shares up to an agreed limit to an investor or through a placement program. It acts like a tapable credit line paid with stock rather than cash, giving the company flexible funding for operations or growth while reducing each existing share's ownership proportion; investors watch these deals because they affect share supply and shareholder value.
accredited investors regulatory
"private placement financing with certain accredited investors (the “Offering”)"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
Rule 506(b) of Regulation D regulatory
"pursuant to an exemption under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What financing did NewcelX Ltd. (NCEL) announce in August 2026?
NewcelX Ltd. announced a private placement where investors will buy 347,134 common shares or pre-funded warrants at $4.033 per share, plus common warrants for up to 347,134 shares at $4.437 per share, providing expected gross proceeds of $1.4 million.
What total proceeds could NewcelX (NCEL) receive from the private placement and warrant exercises?
The private placement is expected to generate $1.4 million in gross proceeds. If the common warrants are cash exercised in full, NewcelX could receive approximately an additional $1.5 million, increasing total potential gross proceeds from this transaction to about $2.9 million.
How will NewcelX (NCEL) use the proceeds from this private placement?
NewcelX intends to use net proceeds, together with current cash and a $25 million equity line, primarily to advance NCEL-101, its lead Type 1 Diabetes program with Eledon Pharmaceuticals, and for working capital and general corporate purposes, supporting ongoing development and operations.
When is NewcelX (NCEL)'s private placement expected to close and what conditions apply?
The offering is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions typical for U.S. securities purchase agreements. If these conditions are not met or contingencies do not occur, the offering may not close as expected.
What restrictions and registration obligations are tied to NewcelX (NCEL)'s private placement?
NewcelX agreed for 60 days not to enter agreements to issue additional common shares or equivalents or to file registration statements, with customary exceptions. It also agreed to use reasonable best efforts to file a resale registration statement within 45 calendar days of the Purchase Agreement date.